Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas

@article{Carralot2005ProductionAC,
  title={Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas},
  author={Jean-Philippe Carralot and Benjamin Weide and Oliver Schoor and Jochen Probst and Birgit Scheel and Regina Teufel and Ingmar Hoerr and Claus Garbe and Hans-Georg Rammensee and Steve Pascolo},
  journal={Genetic Vaccines and Therapy},
  year={2005},
  volume={3},
  pages={6 - 6}
}
BackgroundAnti-tumor vaccines targeting the entire tumor antigen repertoire represent an attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we vaccinated metastatic melanoma patients with autologous amplified tumor mRNA. In order to provide the large quantities of mRNA needed for each patient, the Stratagene Creator™ SMART™ cDNA library construction method was modified and applied to produce libraries derived from the tumors of 15 patients. The quality of… 
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
TLDR
It is demonstrated here that such treatment is feasible and safe (phase 1 criteria) and an increase in antitumor humoral immune response was seen in some patients, however, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumors immunotherapy was not shown in this study and must be evaluated in subsequent trials.
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
TLDR
It is shown here that direct injection of protamine-protected mRNA is feasible and safe and the significant influence of the treatment on the frequency of immunosuppressive cells, the increase of vaccine-directed T cells upon treatment in a subset of patients together with the demonstration of a complete clinical response encourage further clinical investigation of the protamines-mRNA vaccine.
Whole Tumor Antigen Vaccines: Where Are We?
TLDR
The different types of whole tumor antigens that could be used to pulse dendritic cell (DC) ex vivo and in vivo are described and discussed.
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond
TLDR
The developments to optimize mRNA regarding stability, translational efficiency, and immune‐modulating properties to enhance its functionality and efficacy as a therapeutic are reviewed.
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.
TLDR
Induction of CD4(+) and CD8(+) T cell responses was shown for several tumor-associated antigens (TAA) using interferon-γ (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) and Cr-release assays.
Developing peptide vaccines for breast cancer
TLDR
A method for enhancing the immunogenicity of these three HLA-A*0201 (HLA-A2)-restricted breast cancer epitopes was described, and it was found that the BST-2 APL was capable of generating a T-cell response of greater magnitude, and that was also better able to kill breast cancer cells when compared to the corresponding BST- 2 WT peptide.
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics
TLDR
As new cancer antigens come to the forefront with novel RNA encapsulation and targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to initiate patient-specific anti-tumor efficacy.
Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications
TLDR
It was found that this proposed construction can be a promising vaccine against tuberculosis and is ready for wet-lab experiments to approve its efficacy.
Dendritic cell mRNA delivery strategies for ovarian cancer immunotherapy
TLDR
A novel mRNA transfection system utilising mannan for the delivery of mRNA and a strong maturation signal simultaneously to human Mo-DC is investigated, potentially inducing immune responses in the context of multiple MHC class I and II molecules to known/unknown antigens.
...
...

References

SHOWING 1-10 OF 56 REFERENCES
Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1
TLDR
The data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
TLDR
R reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma, which indicates that it belongs to an expanding family of immunogenic testicular antigens.
Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination
TLDR
Results indicate that vaccination with MHC II and/or B7.1 transfected tumour cells induces an efficient immune response, but only if the tumour is weakly immunogenic.
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.
TLDR
It is demonstrated that tumor mRNA, isolated from murine tumor cell lines or from primary human tumor cells microdissected from frozen tissue sections, can be amplified without loss of function and provided the foundations for an effective and broadly applicable treatment that does not require the characterization of the relevant antigenic profile in each patient and will not be limited by tumor tissue availability for antigen preparation.
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
TLDR
The cloning of a cDNA is reported that directs the expression of the antigen recognized by HLA-A2 melanoma patients, and this cDNA corresponds to the transcript of the tyrosinase gene.
Human tumor antigens recognized by T lymphocytes
TLDR
It appears increasingly unlikely that immunization of patients against one of these antigens will cause harmful immunological side effects caused by the expression of the relevant gene in the testis, and these conclusions are further strengthened by immunization studies carried out with mouse tumor antigen P815A, which is encoded by a gene that is also expressed only in thetestis.
Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA.
TLDR
Effective anti-tumor immunity can be induced in mice utilizing RNA-pulsed epidermal cells for in vivo immunization or by injecting RNA intradermally into naïve mice.
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
TLDR
A gene encoding a melanocyte lineage-specific protein (MART-1) that is a widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy is identified and opens possibilities for the development of immunotherapies for patients with melanoma.
Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes
TLDR
Electroporation was the most effective way yielding about 30% EGFP positive cells while less than 1% of DC expressed EGFP using the transferrin receptor transfection system, suggesting that this technology has the potential to induce cytotoxic T-cell response even when low level of antigen is delivered.
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
TLDR
A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line, and it appears to be presented by HLA-A1; anti-MZ 2-E CTLs of the original patient recognized two melanomas cell lines of other HLA -A1 patients that expressed the gene.
...
...